Are angiotensin converting enzyme inhibition and aldosterone antagonism equivalent in hypertensive patients over fifty?

American Journal of Hypertension

Volumn 4, Issue 4, 1991, Pages 356-362

  Plouin, Pierre François ^a   Battaglia, Christiane ^a   Alhenc Gélas, François ^a   Corvol, Pierre ^a  

^a HÔPITAL BROUSSAIS   (France)

Author keywords

Active renin; Aldosterone; Angiotensin converting enzyme; Hypertension; Serum lipids; Spironolactone; Urinary kallikrein

Indexed keywords

ALDOSTERONE; DIPEPTIDYL CARBOXYPEPTIDASE; PERINDOPRIL; RENIN; SPIRONOLACTONE;

ADULT; AGED; ARTICLE; FEMALE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; ORAL DRUG ADMINISTRATION;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; BLOOD PRESSURE; FEMALE; HUMAN; HYPERTENSION; INDOLES; MALE; MIDDLE AGE; PERINDOPRIL; RENIN-ANGIOTENSIN SYSTEM; SPIRONOLACTONE; SUPPORT, NON-U.S. GOV'T; THERAPEUTIC EQUIVALENCY;

EID: 0025877871     PISSN: 08957061     EISSN: 19417225     Source Type: Journal    
DOI: 10.1093/ajh/4.4.356     Document Type: Article

References (29)

1. Brown JJ, Leckie BJ, Lever AF, et al: The renin-angiotensin system and the regulation of the circulation, in Robertson JIS (ed): Handbook of Hypertension. Amsterdam, Elsevier, 1983, pp 278-323.
2. Brunner HR, Nussberger J, Waeber B: Effects of angiotensin converting enzyme inhibition: a clinical point of view. J Cardiovasc Pharmacol 1985;7(Suppl 4):73-81.
3. Macfadyen RJ, Lees KR, Reid JL: Perindopril: a review of its pharmacokinetics and clinical pharmacology. Drugs 1990;39(Suppl l):49-63.
4. Drizd T, Dannenberg AL, Engel A: Blood pressure levels in persons 18-74 years of age in 1976-1980 and trends in blood pressure from 1960-1980 in the United States. US Dept of Health and Human Services publication No. (PHS) 86-1684, Series 11, No. 224. Washington, DC, US Government Printing Office, 1986.
5. Levinsky NG: The renal kallikrein-kinin system. Circ Res 1979;44:441-451.
6. McCaa RE: Role of the renin-angiotensin-aldosterone and kallikrein-kinin systems in the control of fluid and electrolyte metabolism, renal function, and arterial blood pressure. Clin Exp Hypertens [A] 1982;4:1593-1611.
7. Ménard J, Devries C, Plouin PF, Tugayé A: Investigation for secondary hypertension, in Sleight P, Freis E (eds): Hypertension. London, Butterworth, 1982, pp 117-134.
8. Galen FX, Devaux C, Atlas A, et al: New monoclonal antibodies directed against human renin: powerful tools for the investigation of the renin system. J Clin Invest 1984;74:723-735.
9. Ménard J, Guyenne TT, Corvol P, et al: Direct immuno-metric assay of active renin in human plasma. J Hypertens 1985;3(Suppl 3):S275-S278.
10. Pham-Huu-Trung MT, Corvol P: A direct determination of plasma aldosterone. Steroids 1974;24:587-598.
11. Cambien F, Alhenc-Gélas F, Herbeth B, et al: Familial resemblance of plasma angiotensin-converting enzyme level: the Nancy study. Am J Hum Genet 1988;43:774-780.
12. Joint National Committee: The 1988 report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med 1988;148:1023-1038.
13. Bulher FR: Antihypertensive treatment according to age, plasma renin and race. Drugs 1988;35:495-503.
14. Murray GD, Lesaffre E, Robertson JIS: Interpreting age-related aspects of ntihypertensive treatment: statistical defects and their remedy. J Hypertens 988;6(Suppl 1):S121-S126.
15. Kaplan NM: Age and the response to antihypertensive drugs. Am J Hypertens 1989;2:213-215.
16. Brunner HR, Ménard J, Waeber B, et al: Treating the individual hypertensive patient: considerations on dose, sequential monotherapy and drug combinations. J Hypertens 1990;8:3-11.
17. Hypertension Detection and Follow-up Program Cooperative Group: Five-year findings of the Hypertension Detection and Follow-up Program. II. Mortality by race, sex and age. JAMA 1979;242:2572-2577.
18. Amery A, Birkenhager W, Brixko P, et al: Mortality and morbidity results from the European Working Party on High Blood Pressure in the Elderly trial. Lancet 1985;1:1349-1354.
19. Amery A, Berthaux P, Bulpitt C, et al: Glucose intolerance during diuretic therapy. Results of trial by the European Working Party on Hypertension in the Elderly. Lancet 1978;1:681-683.
20. J ames MA, Jones J V: V entricular arrhythmia in untreated newly presenting hypertensive patients compared to a matched normal population. J Hypertens 1989;7:409-415.
21. Winer BM, Lubber WB, Colton T: Antihypertensive action of diuretics: comparative study of an aldosterone antagonist and a thiazide alone and together. JAMA 1968;204:775-779.
22. Jeunemaitre X, Charru A, Chatellier G, et al: Long term metabolic effects of spironolactone and thiazides combined with potassium sparing agents for treatment of essential hypertension. Am J Cardiol 1988;62:1072-1077.
23. Falch DK, Schreiner A: The effect of spironolactone on lipid, glucose and uric acid levels in blood during longterm administration to hypertensives. Acta Med Scand 1983;213:27-30.
24. Plouin PF, Alhenc-Gélas F, Aldigier JC, et al: Effect of perindopril (S-9490) on blood pressure and the renin-angiotensin aldosterone system in hypertensive men. Clin Exper Hypertens 1987;A9:1988 (abstract)
25. Vardan S, Mehrotra KG, Mookherjee S, et al: Efficacy and reduced metabolic side effects of a 15-mg chlorthalidone formulation in the treatment of mild hypertension. A Multicenter study. JAMA 1987;258:484-488.
26. Masugi F, Ogihara T, Hashizume K, et al: Change in plasma lipids and uric acid with sodium loading and sodium depletion in patients with essential hypertension. J Hum Hypertens 1988;1:293-298.
27. Margolius HS, Horwitz D, Geller RW, et al: Urinary kal-likrein excretion in normal man. Relationships to sodium intake and sodium-retaining steroids. Circ Res 1974;35:812-819.
28. Margolius HS, Horwitz D, Pisano JJ, Keiser HR: Urinary kallikrein excretion in hypertensive man. Relationships to sodium intake and sodium-retaining steroids. Circ Res 1974;35:820-825.
29. Misumi J, Alhenc-Gélas F, Marre M, et al: Regulation of kallikrein and renin release by the isolated perfused rat kidney. Kidney Int 1983;24:58-65.